Table 1.
BMT Patient Characteristics and Patient DNA Detected
| Patient no. | Disease | Patient HLA-A | Donor HLA-A | Difference∗ | Patients (%) |
|---|---|---|---|---|---|
| BME14 | AML | A*02:05:01/A*03:01:01:01 | A*02:05:01/A*01:01:01:01 | 11,6 | 0.000 |
| BME20 | MDS | A*29:02:01:01/A*26:01:01 | A*01:01:01:01/A*26:01:01 | 12,6 | 0.001 |
| BME18 | AML | A*03:01:01:01/A*30:01:01 | A*11:01:01/A*30:01:01 | 7,5 | 0.019 |
| BME10 | AML | A*32:01:01/A*34:02:01 | A*01:01:01:01/A*34:02:01 | 12,3 | 0.030 |
| BME19 | AML | A*24:02:01:01/A*68:01:01:01 | A*32:01:01/A*68:01:01:01 | 6,7 | 0.052 |
| BME25 | ALL | A*01:01:01:01/A*03:01:01:01 | A*33:01:01/A*03:01:01:01 | 12,11 | 0.060 |
| BME30 | AML | A*03:01:01:01/A*24:02:01:01 | A*03:01:01:01/A*01:01:01:01 | 7,6 | 0.136 |
| BME27 | AML | A*02:01:01:01/A*24:02:01:01 | A*02:01:01:01/A*02:01:01:01 | 7 | 0.140 |
| BME16 | AML | A*02:XX/A*26:XX | A*02:xx/A*03:xx | 6,9 | 0.189 |
| BME11 | AML | A*30:02:01/A*74:01 | A*68:02:01:01/A*74:01 | 8,2 | 0.190 |
| BME4 | AML-M6 | A*02:01:01:01/A*29:02:01:01 | A*02:01:01:01/A*68:01:01:01 | 6,5 | 0.312 |
| BME26 | ALL | A*11:01:01/A*30:01:01 | A*25:01:01/A*30:01:01 | 6,9 | 0.328 |
| BME1 | MM | A*02:01:01:01/A*23:01:01 | A*30:xx/A*02:xx | 4,7 | 0.416 |
| BME22 | CLL | A*02:01:01:01/A*66:01 | A*01:01:01:01/A*66:01 | 11,9 | 0.640 |
| BME21 | MCL | A*68:02:01:01/A*29:02:01:01 | A*30:01:01/A*29:02:01:01 | 8,6 | 0.750 |
| BME29 | AML | A*11:01:01/A*26:01:01 | A*11:01:01/A*11:01:01 | 6 | 0.863 |
| BME23 | DLBCL | A*02:01:01:01/A*26:01:01 | A*02:01:01:01/A*02:01:01:01 | 9 | 1.110 |
| BME24 | HD | A*01:01:01:01/A*29:02:01:01 | A*30:02:01/A*29:02:01:01 | 13,12 | 1.470 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; HD, Hodgkin disease; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma.
∗
Number of SNP differences between unique alleles (bold) and between the unique patient and shared alleles.